Replica Analytics Ltd.

Replica Analytics Ltd. specializes in advanced data analytics solutions, leveraging artificial intelligence to enhance data privacy and utility for biopharmaceutical and healthcare sectors, thereby supporting better decision-making processes. Founded in 2019 and headquartered in Ottawa, Canada, Replica Analytics Ltd. focuses on providing cutting-edge data analytics services.

The company was acquired by Aetion, Inc. in January 2022, which aimed to enhance access to fit-for-purpose real-world evidence data. The founder’s prior ventures are not specified. The company has engaged in 3 total deals, with the latest funding round totaling USD 1.

00 mn, attracting notable investors including Fight Against Cancer Innovation Trust and MiTAC International Corp. Replica Analytics Ltd. offers an advanced data analytics platform that focuses on AI-driven technology to improve data privacy and utility. Their offerings include tools for risk-based de-identification, synthetic data generation, and virtual patient modeling, catering to the needs of biopharma companies, regulatory agencies, and healthcare organizations primarily in North America and Europe.

Replica Analytics Ltd. generates revenue through a business-to-business model, providing subscriptions to its analytics platform and related services. Clients include major biopharmaceutical firms and healthcare organizations, engaging in service agreements that typically span annual or multi-year contracts. While specific pricing is not publicly disclosed, the platform's features, including compliance tools and enhanced data capabilities, are central to the client value proposition.

Following its acquisition by Aetion, Inc. , Replica Analytics Ltd. aims to address challenges in accessing fit-for-purpose data for real-world evidence solutions. This acquisition is expected to support the development and launch of new advanced analytics tools.

The company plans to leverage the recent funding of USD 1. 00 mn to bolster its product development efforts and expand its reach within the healthcare and biopharmaceutical markets.